FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.8.3  |  FHIR Version n/a  User: [n/a]

386978004: Basiliximab (substance)


Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jan 2003. Module: SNOMED CT core

Descriptions:

Id Description Lang Type Status Case? Module
1461156013 Basiliximab (substance) en Fully specified name Active Entire term case insensitive (core metadata concept) SNOMED CT core
1481092016 Basiliximab en Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT core
3264031000005112 basiliximab da Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) Danish module (core metadata concept)


0 descendants.

Expanded Value Set


Outbound Relationships Type Target Active Characteristic Refinability Group Values
Basiliximab (substance) Is a monoklonalt antistof-agens false Inferred relationship Some
Basiliximab (substance) Is a murin-humant monoklonalt IgG-antistof false Inferred relationship Some
Basiliximab (substance) This attribute specifies the behavior that a substance will exhibit or participate in, given the appropriate context. Murine-human monoclonal immunoglobulin G antibody false Inferred relationship Some
Basiliximab (substance) This attribute specifies the behavior that a substance will exhibit or participate in, given the appropriate context. A substance that modifies the immune response or the functioning of the immune system. true Inferred relationship Some
Basiliximab (substance) Is a Immunosuppressant (substance) true Inferred relationship Some
Basiliximab (substance) Is a Monoclonal antibody true Inferred relationship Some

Inbound Relationships Type Active Source Characteristic Refinability Group
Product containing basiliximab (medicinal product) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Basiliximab (substance) Inferred relationship Some 1
Basiliximab 20mg/vial powder The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Basiliximab (substance) Inferred relationship Some
basiliximab 20 mg injektionsvæske (pulver til rekonstitution) + solvens The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Basiliximab (substance) Inferred relationship Some
basiliximab 10 mg injektionsvæske (pulver til rekonstitution) + solvens The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Basiliximab (substance) Inferred relationship Some
Basiliximab 10 mg powder for solution for injection vial This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. True Basiliximab (substance) Inferred relationship Some 1
Basiliximab 10 mg powder for solution for injection vial The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). True Basiliximab (substance) Inferred relationship Some 1
Basiliximab 20 mg powder for solution for injection vial The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). True Basiliximab (substance) Inferred relationship Some 1
Basiliximab 20 mg powder for solution for injection vial This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. True Basiliximab (substance) Inferred relationship Some 1
Basiliximab-containing product in parenteral dose form The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Basiliximab (substance) Inferred relationship Some 1
Product containing only basiliximab (medicinal product) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Basiliximab (substance) Inferred relationship Some 1
Basiliximab only product in parenteral dose form The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Basiliximab (substance) Inferred relationship Some 1

This concept is not in any reference sets

Back to Start